AI Article Synopsis
- Modern treatments for blood cancers have greatly enhanced patient outcomes, but many cancer drugs can lead to serious heart-related issues.
- Understanding these potential cardiovascular complications, such as heart failure and rhythm disturbances, is essential for optimal patient care.
- The review highlights the symptoms, prevention strategies, and management of heart toxicity in patients receiving cancer treatments or stem cell transplants.
Article Abstract
Modern treatment modalities in hematology have improved clinical outcomes of patients with hematological malignancies. Nevertheless, many new or conventional anticancer drugs affect the cardiovascular system, resulting in various cardiac disorders, including left ventricular dysfunction, heart failure, arterial hypertension, myocardial ischemia, cardiac rhythm disturbances, and QTc prolongation on electrocardiograms. As these complications may jeopardize the significantly improved outcome of modern anticancer therapies, it is crucial to become familiar with all aspects of cardiotoxicity and provide appropriate care promptly to these patients. In addition, established and new drugs contribute to primary and secondary cardiovascular diseases prevention. This review focuses on the clinical manifestations, preventive strategies, and pharmaceutical management of cardiotoxicity in patients with hematologic malignancies undergoing anticancer drug therapy or hematopoietic stem cell transplantation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412591 | PMC |
| http://dx.doi.org/10.3390/ph15081007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Severe Reversible Heart Failure Enhanced by Sorafenib Treatment for Hepatocellular Carcinoma.
Cureus
January 2025
Medical Oncology, Instituto Português de Oncologia de Coimbra Francisco Gentil, Coimbra, PRT.
The multitarget oral tyrosine kinase inhibitor sorafenib is an effective first-line treatment option in unresectable hepatocellular carcinoma. Through its mechanism of action, it has been associated with cardiotoxicity, mainly hypertension, which is usually low-grade and well-managed with behavioral changes and antihypertensor treatment adjustment, if needed. Acute, symptomatic heart failure is rarely described.
View Article and Find Full Text PDFLeft ventricular global longitudinal strain in patients treated with immune checkpoint inhibitors.
Front Oncol
December 2024
Department of Cardiology, University of Health Sciences Bursa Yuksek Ihtisas Training and Research Hospital, Bursa, Türkiye.
Background: Immune checkpoint inhibitors (ICI) are generally associated with rare cardiac side effects, yet instances like myocarditis can be fatal. Therefore, detecting and managing left ventricular dysfunction early in ICI therapy is vital.
Objectives: This study aims to evaluate whether left ventricular global longitudinal strain (LV GLS) is a predictor for early detection of cardiac dysfunction in patients receving ICI.
Cardiotoxicity and peri-operative considerations in immune checkpoint inhibitor and chimeric antigen receptor T-cell therapy: a narrative review.
Anaesthesia
January 2025
Department of Cardiovascular Medicine, Department of Medicine, Lahey Hospital and Medical Center, Burlington, MA, USA.
Introduction: Immunotherapy has transformed cancer treatment, particularly with immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy. Despite their efficacy, these therapies can induce cardiotoxicity, presenting significant clinical challenges. Immune checkpoint inhibitors can cause myocarditis; pericarditis; arrhythmias; and myocardial infarction through immune-mediated inflammation.
View Article and Find Full Text PDFMitophagy in Doxorubicin-Induced Cardiotoxicity: Insights into Molecular Biology and Novel Therapeutic Strategies.
Biomolecules
December 2024
Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China.
Doxorubicin is a chemotherapeutic drug utilized for solid tumors and hematologic malignancies, but its clinical application is hampered by life-threatening cardiotoxicity, including cardiac dilation and heart failure. Mitophagy, a cargo-specific form of autophagy, is specifically used to eliminate damaged mitochondria in autophagosomes through hydrolytic degradation following fusion with lysosomes. Recent advances have unveiled a major role for defective mitophagy in the etiology of DOX-induced cardiotoxicity.
View Article and Find Full Text PDFCardiotoxicity in Breast Cancer: Impact of Clinical Classifications and Treatment on Heart Health.
Cancers (Basel)
December 2024
Department of Clinical Discipline, Faculty of Medicine and Pharmacy, University of Oradea, 410068 Oradea, Romania.
Background/objectives: Cardio-oncology has become essential in addressing cardiovascular complications from cancer therapies. While advancements in treatments have improved survival rates, they also increase cardiovascular risks. This study evaluates the cardiotoxic effects of cytostatic treatments, examining the relationship between tumor characteristics, such as histopathology and TNM classification, and cardiovascular complications, aiming to improve cardiotoxicity prevention and management in oncology patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!